AmerisourceBergen Drug Corporation
AmerisourceBergen Drug Corporation, commonly referred to as AmerisourceBergen, is a leading global healthcare solutions provider headquartered in the United States. Founded in 2001, the company has established itself as a key player in the pharmaceutical distribution industry, serving healthcare providers across North America and beyond. Specialising in pharmaceutical distribution, AmerisourceBergen offers a comprehensive range of services, including supply chain management, logistics, and consulting. The company is renowned for its commitment to improving patient access to medications and enhancing the efficiency of healthcare delivery. With a strong market position, AmerisourceBergen has achieved significant milestones, including strategic partnerships and innovative solutions that set it apart in the competitive landscape.
DitchCarbon Score
How does AmerisourceBergen Drug Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AmerisourceBergen Drug Corporation's score of 36 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AmerisourceBergen Drug Corporation's reported carbon emissions
In 2021, AmerisourceBergen Drug Corporation reported significant carbon emissions, totalling approximately 11,293,675 kg CO2e for Scope 1 and about 96,472,630 kg CO2e for Scope 2 on a market-based approach globally. The company also disclosed Scope 3 emissions, which included approximately 21,151,776,940 kg CO2e from purchased goods and services, 741,348,030 kg CO2e from downstream transportation and distribution, and 72,039,560 kg CO2e from employee commuting. In the United States, the emissions for 2021 were approximately 21,309,311 kg CO2e for Scope 1 and about 66,627,361 kg CO2e for Scope 2. In Canada, the reported emissions were approximately 908,804 kg CO2e for Scope 1 and 776,292 kg CO2e for Scope 2. Despite the extensive emissions data, AmerisourceBergen has not set specific reduction targets or initiatives as part of their climate commitments, as indicated by the absence of documented reduction targets or SBTi (Science Based Targets initiative) commitments. The emissions data is cascaded from their parent company, Cencora, Inc., reflecting their current subsidiary relationship. Overall, AmerisourceBergen's emissions profile highlights the substantial carbon footprint associated with their operations, particularly in Scope 3 emissions, which are critical for understanding the full impact of their supply chain and business activities.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | 109,727,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 105,581,090 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,532,581,490 | - | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AmerisourceBergen Drug Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
